EGFR and neoplasm: Upon the univariable logistic regression, female gender (p = 0.020), line of treatment (p = 0.007), the presence of EGFR+ tumours (p = 0.019), pre-treatment lymphocyte count (p = 0.017), sixth-week lymphocyte count (p = 0.017), and sixth-week NLRs of ≥3 (p = 0.003) and ≥5 (p = 0.028) were significantly associated with development of primary resistance (Table 2).